| Thomas Glasgow, MD | |
|
2161 S Lamar Blvd, Oxford, MS 38655-5223 | |
| (662) 234-1791 | |
| (662) 234-4790 |
| Full Name | Thomas Glasgow |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 56 Years |
| Location | 2161 S Lamar Blvd, Oxford, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316913783 | NPI | - | NPPES |
| 00116480 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 05610 (Mississippi) | Secondary |
| 207Q00000X | Family Medicine | 05610 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Home Care And Hospice North Mississippi | Batesville, MS | Home health agency |
| Sta Home Health And Hospice | Greenwood, MS | Home health agency |
| Kindred At Home | Tupelo, MS | Home health agency |
| North Mississippi Medical Center | Tupelo, MS | Hospital |
| Baptist Memorial Hospital North Ms | Oxford, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Mississippi Medical Clinics Inc | 6103736665 | 113 |
News Archive
The U.S. Food and Drug Administration today approved Abraxane for patients with advanced pancreatic cancer, following 7 years of rigorous clinical trials overseen by Scottsdale Healthcare and the Translational Genomics Research Institute.
The Endocrine Society and Society for Women's Health Research (SWHR) are co-sponsoring a Congressional briefing on July 10 to examine the need to include more female subjects in preclinical and clinical biomedical research - a move that could revolutionize medical research and scientific discovery.
Critical Outcome Technologies Inc. announced more positive results today from animal experiments carried out at a prominent Canadian cancer research facility. This new series of experiments adds to the impressive data package for COTI-2, demonstrating efficacy both as a single agent and in combination with current first line therapies, as well as low toxicity in several different animal models of human cancers.
The Associated Press terms it a "symbol" of the "federal government's budget dysfunction" because physicians again are facing a steep cut in Medicare payments unless Congress intervenes. This time, though, such action will be considered in the context of other difficult budget questions.
› Verified 2 days ago
| Entity Name | North Mississippi Medical Clinics Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053469486 PECOS PAC ID: 6103736665 Enrollment ID: O20040127000582 |
News Archive
The U.S. Food and Drug Administration today approved Abraxane for patients with advanced pancreatic cancer, following 7 years of rigorous clinical trials overseen by Scottsdale Healthcare and the Translational Genomics Research Institute.
The Endocrine Society and Society for Women's Health Research (SWHR) are co-sponsoring a Congressional briefing on July 10 to examine the need to include more female subjects in preclinical and clinical biomedical research - a move that could revolutionize medical research and scientific discovery.
Critical Outcome Technologies Inc. announced more positive results today from animal experiments carried out at a prominent Canadian cancer research facility. This new series of experiments adds to the impressive data package for COTI-2, demonstrating efficacy both as a single agent and in combination with current first line therapies, as well as low toxicity in several different animal models of human cancers.
The Associated Press terms it a "symbol" of the "federal government's budget dysfunction" because physicians again are facing a steep cut in Medicare payments unless Congress intervenes. This time, though, such action will be considered in the context of other difficult budget questions.
› Verified 2 days ago
| Entity Name | Southeastern Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356379382 PECOS PAC ID: 2466364997 Enrollment ID: O20050407000866 |
News Archive
The U.S. Food and Drug Administration today approved Abraxane for patients with advanced pancreatic cancer, following 7 years of rigorous clinical trials overseen by Scottsdale Healthcare and the Translational Genomics Research Institute.
The Endocrine Society and Society for Women's Health Research (SWHR) are co-sponsoring a Congressional briefing on July 10 to examine the need to include more female subjects in preclinical and clinical biomedical research - a move that could revolutionize medical research and scientific discovery.
Critical Outcome Technologies Inc. announced more positive results today from animal experiments carried out at a prominent Canadian cancer research facility. This new series of experiments adds to the impressive data package for COTI-2, demonstrating efficacy both as a single agent and in combination with current first line therapies, as well as low toxicity in several different animal models of human cancers.
The Associated Press terms it a "symbol" of the "federal government's budget dysfunction" because physicians again are facing a steep cut in Medicare payments unless Congress intervenes. This time, though, such action will be considered in the context of other difficult budget questions.
› Verified 2 days ago
| Entity Name | Mississippi Emergency Physician Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710220678 PECOS PAC ID: 2264672492 Enrollment ID: O20130710000827 |
News Archive
The U.S. Food and Drug Administration today approved Abraxane for patients with advanced pancreatic cancer, following 7 years of rigorous clinical trials overseen by Scottsdale Healthcare and the Translational Genomics Research Institute.
The Endocrine Society and Society for Women's Health Research (SWHR) are co-sponsoring a Congressional briefing on July 10 to examine the need to include more female subjects in preclinical and clinical biomedical research - a move that could revolutionize medical research and scientific discovery.
Critical Outcome Technologies Inc. announced more positive results today from animal experiments carried out at a prominent Canadian cancer research facility. This new series of experiments adds to the impressive data package for COTI-2, demonstrating efficacy both as a single agent and in combination with current first line therapies, as well as low toxicity in several different animal models of human cancers.
The Associated Press terms it a "symbol" of the "federal government's budget dysfunction" because physicians again are facing a steep cut in Medicare payments unless Congress intervenes. This time, though, such action will be considered in the context of other difficult budget questions.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas Glasgow, MD 2161 S Lamar Blvd, Oxford, MS 38655-5223 Ph: (662) 234-1791 | Thomas Glasgow, MD 2161 S Lamar Blvd, Oxford, MS 38655-5223 Ph: (662) 234-1791 |
News Archive
The U.S. Food and Drug Administration today approved Abraxane for patients with advanced pancreatic cancer, following 7 years of rigorous clinical trials overseen by Scottsdale Healthcare and the Translational Genomics Research Institute.
The Endocrine Society and Society for Women's Health Research (SWHR) are co-sponsoring a Congressional briefing on July 10 to examine the need to include more female subjects in preclinical and clinical biomedical research - a move that could revolutionize medical research and scientific discovery.
Critical Outcome Technologies Inc. announced more positive results today from animal experiments carried out at a prominent Canadian cancer research facility. This new series of experiments adds to the impressive data package for COTI-2, demonstrating efficacy both as a single agent and in combination with current first line therapies, as well as low toxicity in several different animal models of human cancers.
The Associated Press terms it a "symbol" of the "federal government's budget dysfunction" because physicians again are facing a steep cut in Medicare payments unless Congress intervenes. This time, though, such action will be considered in the context of other difficult budget questions.
› Verified 2 days ago
Eric Paul Dahl, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 1487 Belk Blvd, Oxford, MS 38655 Phone: 662-234-1090 Fax: 662-234-0432 | |
Shavonne Bridgette Doyle, NP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2908 S Lamar Blvd Ste 100, Oxford, MS 38655 Phone: 662-281-0112 | |
Hunter Davis Haley, Family Medicine Medicare: Medicare Enrolled Practice Location: 497 Azalea Dr Ste 102, Oxford, MS 38655 Phone: 662-513-2000 | |
Willis N Dabbs, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1487 Belk Blvd, Oxford, MS 38655 Phone: 662-234-1090 Fax: 662-234-0432 | |
Ana-maria Nae Benefield, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1397 Belk Blvd, Oxford, MS 38655 Phone: 622-236-4675 | |
Shelly Renae-hughes Alamry, NP-C Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2706 W Oxford Loop Ste 103, Oxford, MS 38655 Phone: 662-380-5445 Fax: 662-580-5517 | |
Dr. Terri Jo Teague, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2173 S Lamar Blvd, Oxford, MS 38655 Phone: 662-234-6553 |